omniture
logo
Search
深圳市亦诺微医药科技有限公司 Immvira Co. Ltd
Media Room

Photo News

rss
ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

2024-03-15 13:56 1373
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results

MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results

2023-11-10 08:00 1603
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

2023-08-23 10:51 1494
ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

2023-06-07 08:00 2203
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

2023-04-21 09:06 1848
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

2023-04-19 08:29 1540
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

2023-03-30 08:00 1546
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma

ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma

2023-02-09 08:00 1663
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round

ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round

2022-10-26 14:26 1786
ImmVira announced to launch the construction of Global R&D and Commercialization Base

ImmVira announced to launch the construction of Global R&D and Commercialization Base

2022-10-18 16:22 993
ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation

ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation

2022-08-08 08:30 1432
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities

ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities

2022-07-21 08:00 1437
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

2022-04-20 08:00 1509
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China

ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China

2022-03-02 09:07 1071
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors

ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors

2022-01-25 08:30 1345
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

2022-01-19 08:30 1352
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial

ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial

2021-08-11 10:45 1223
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial

ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial

2021-08-06 19:50 2385
ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials

ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials

2021-07-19 08:30 1351
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

2021-06-12 11:16 3011
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021

ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021

2021-06-02 16:14 1097
12